Ongoing important trials
PIPAC — pressurized intraperitoneal aerosol chemotherapy for peritoneal metastasis
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in patients with peritoneal carcinomatosis (örnek kayıt programları)
- Phase
- Phase II
- Recruitment
- Completed
- Results maturity
- Primary analysis
- Publication
- Peer-reviewed
- Regulatory approval
- No regulatory approval
- NCT
- NCT03287375
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? Delivering drugs into the abdomen with a special method is being studied for cancer spread on the peritoneum. It is experimental / center-selected.
Why promising? Local drug-delivery approach when systemic options are limited in peritoneal disease.
What is not proven? OS superiority; replacement for standard HIPEC; a single regimen standard.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
NCT03287375 is one example record; the PIPAC field is multicenter and heterogeneous. Current recruitment must be verified per NCT.
Cancer / population: Peritoneal metastasis, Colon — Peritoneal karsinomatozis (kolorektal ve diğer)
Intervention: PIPAC (çeşitli sitotoksik rejimler)
Primary endpoint: Protokole göre (güvenlik / PCI / patolojik yanıt)
Limitations: Heterojen protokoller; mükerrer PIPAC NCT’leri birleştirilmez.